Finally, by testing the available LSD1 inhibitors in human ETP-ALL, we noticed that scaffolding LSD1 inhibitor (SP-2509 and clinical successor SP-2577, also known as seclidemstat) has greater activity on its own as well as more synergy with JAK/STAT pathway inhibitors than the catalytic LSD1 inhibitors (e.g. GSK-LSD1, ORY-1001), which highlights in addition to the demethylase activity, the scaffolding role of LSD1 in human ETP-ALL to maintain the repression of ZEB2 target genes such as pro-apoptotic genes (e.g. BCL2L11(BIM). This evidence concerns the gene MBD2 and acute lymphoblastic leukemia.